Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination With Carboplatin and Etoposide (PaCE) Chemotherapy Versus Carboplatin and Etoposide (CE) Alone in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer. The MATISSE Study

NCT01555710 is registered in ClinicalTrials.gov with Alaunos Therapeutics as lead sponsor.

NCT NCT01555710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01555710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination With Carboplatin and Etoposide (PaCE) Chemotherapy Versus Carboplatin and Etoposide (CE) Alone in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer. The MATISSE Study
Lead sponsor
Alaunos Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
June 8, 2012
Completion date
December 2, 2014
Enrollment
188 (actual)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small cell lung cancer